Abstract
4/2009
vol. 5
The influence of aspirin resistance on non-fatal coronary events following percutaneous coronary interventions
Arch Med Sci 2009; 5, 4: 531-538
Online publish date: 2009/12/30
Introduction: Aspirin resistance is associated with unfavourable prognosis, including a higher incidence of myocardial infarction, stroke, and cardiovascular death among stable cardiovascular patients, a higher incidence of re-occlusion after peripheral angioplasty, and myonecrosis following elective percutaneous coronary interventions (PCI). The objective of this study was to evaluate the relationship between aspirin resistance and non-fatal clinical endpoints during the long term follow-up following successful PCI.
Material and methods: A total of 100 subjects with angiographically diagnosed coronary artery disease and treated with elective, non-urgent intracoronary stent implantation between October 2001 and June 2002 were enrolled in the study. All patients were under regular aspirin (300 mg) treatment. PFA-100 analyzer was used to assess the platelet functions. Aspirin resistance was defined as a collagen/epinephrine closure time (CTCEPI) < 186 s. The study end-point was the composite of non-fatal coronary events which included non-fatal MI, coronary artery bypass graft surgery (CABG) or repeat PCI, during the 2-year follow-up period after the index PCI.
Results: The incidence of aspirin resistance was found to be significantly higher (p = 0.021) in patients with non-fatal coronary events (22.4%) compared to those who did not have (5.9%). Aspirin resistance was found to be an independent risk factor for non-fatal coronary events after adjusted for other potential risk factors (p = 0.019).
Conclusions: Despite regular treatment with aspirin, the incidence of aspirin resistance was significantly higher in patients who developed non-fatal coronary events on long term follow-up following elective PCI. Thus, these findings suggest that aspirin resistance might be an important risk factor that could affect the outcome following PCIs.
Material and methods: A total of 100 subjects with angiographically diagnosed coronary artery disease and treated with elective, non-urgent intracoronary stent implantation between October 2001 and June 2002 were enrolled in the study. All patients were under regular aspirin (300 mg) treatment. PFA-100 analyzer was used to assess the platelet functions. Aspirin resistance was defined as a collagen/epinephrine closure time (CTCEPI) < 186 s. The study end-point was the composite of non-fatal coronary events which included non-fatal MI, coronary artery bypass graft surgery (CABG) or repeat PCI, during the 2-year follow-up period after the index PCI.
Results: The incidence of aspirin resistance was found to be significantly higher (p = 0.021) in patients with non-fatal coronary events (22.4%) compared to those who did not have (5.9%). Aspirin resistance was found to be an independent risk factor for non-fatal coronary events after adjusted for other potential risk factors (p = 0.019).
Conclusions: Despite regular treatment with aspirin, the incidence of aspirin resistance was significantly higher in patients who developed non-fatal coronary events on long term follow-up following elective PCI. Thus, these findings suggest that aspirin resistance might be an important risk factor that could affect the outcome following PCIs.
Keywords
aspirin resistance, platelet, percutaneous coronary intervention
Integrated with